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2ABSTRACT 
Glioblastoma multiforme (GBM) is a grade IV astrocytoma, which is the most aggressive form 
of brain tumor. The standard of care for this disease includes surgery, radiotherapy and 
temozolomide (TMZ) chemotherapy. Poor accumulation of TMZ at the tumor site, tumor 
resistance to drug and dose-limiting bone marrow toxicity eventually reduce the success of this 
treatment. Herein, we have encapsulated > 500 drug molecules of TMZ into the biocompatible 
protein nanocage, apoferritin (AFt), using a ‘nanoreactor’ method (AFt-TMZ). AFt is 
internalized by transferrin receptor 1-mediated endocytosis and is therefore able to facilitate 
cancer cell-uptake and enhance drug efficacy. Following encapsulation, the protein cage 
retained its morphological integrity and surface charge, hence its cellular recognition and 
uptake are not affected by the presence of this cargo. Additional benefits of AFt include 
maintenance of TMZ stability at pH 5.5 and drug release under acidic pH conditions, 
encountered in lysosomal compartments. MTT assays revealed that the encapsulated agents 
displayed significantly increased anti-tumor activity in U373V (vector control) and, 
remarkably the isogenic, U373M (MGMT expressing TMZ-resistant) GBM cell lines, with 
GI50 values < 1.5 μM for AFt-TMZ, compared to 35 μM and 376 µM for unencapsulated TMZ 
against U373V and U373M, respectively. The enhanced potency of AFt-TMZ was further 
substantiated by clonogenic assays. Potentiated G2/M cell cycle arrest following exposure of 
cells to AFt-TMZ indicated an enhanced DNA damage burden. Indeed, increased O6-
methylguanine (O6-MeG) adducts in cells exposed to AFt-TMZ and subsequent generation of 
γH2AX foci, support the hypothesis that AFt significantly enhances the delivery of TMZ to 
cancer cells in vitro; overwhelming the direct O6-MeG repair conferred by MGMT. We have 
additionally encapsulated > 500 molecules of the N3-propargyl imidazotetrazine analog (N3P), 
developed to combat TMZ resistance, and demonstrated significantly enhanced activity of AFt-
N3P against GBM and colorectal carcinoma cell lines. These studies support the use of AFt as 
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3a promising nano-delivery system for targeted delivery, lysosomal drug release and enhanced 
imidazotetrazine potency for treatment of GBM and wider-spectrum malignancies.
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41. INTRODUCTION
Glioblastoma multiforme (GBM), a grade (IV) astrocytoma, is the most prevalent and 
aggressive adult central nervous system (CNS) tumor; presenting heterogeneous, highly 
angiogenic, invasive and migratory characteristics.1-4 GBM cells infiltrate healthy areas of the 
brain and are thus surrounded by a blood-brain tumor barrier and blood-brain barrier (BBB).5 
Surgical resection of the tumor followed by radiotherapy coupled with temozolomide (TMZ; 
Figure 1a) chemotherapy confers a median survival rate of ~ 15 months.6 Despite the fact that 
TMZ is able to relatively easily cross the BBB by diffusion, there are concerns associated with 
poor accumulation of TMZ at the tumor site due to presence of active drug efflux transport 
proteins such as P-glycoprotein (Pgp) in the BBB and short TMZ plasma half-life (t½).7,8 
Indeed, it has been estimated that < 1% of administered drug reaches the brain.9 Furthermore, 
TMZ therapy harbors dose-limiting bone marrow toxicity, hence presenting an additional 
barrier to successful treatment.10 
Intracellular drug resistance mechanisms further exacerbate efficacy. TMZ is a DNA 
methylating prodrug. Upon degradation, the active methyldiazonium cation is released and 
reacts with DNA purine bases, methylating N3-adenine, O6- and N7-guanine.11 O6-
methylguanine (O6-MeG) is the most cytotoxic product produced.12,13 The mechanism of 
action of TMZ has been established14-16 and it is now accepted that a deficiency in DNA 
mismatch repair (MMR) leading to O6-MeG-thymine mismatch tolerance and overexpression 
of O6-methylguanine-DNA methyltransferase (MGMT), which removes the methyl group 
from the O6 position of guanine (restoring normal guanine), are major causes of TMZ 
resistance in vitro and clinically.17,18 To overcome TMZ resistance, analogs of TMZ have been 
developed, whereby N3-methyl substitutions with for example N3-propargyl (N3P), have 
allowed analogs to evade recognition and removal by MGMT and exert activity independent 
of DNA mismatch repair (MMR) status.19,20
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5To enhance brain tumor drug accumulation for greater efficacy and to prevent dose-
related toxicity, one approach has been to utilize drug delivery systems (DDS) for targeted drug 
delivery to tumors.21-24 Apoferritin (AFt; 480 kDa) is a biocompatible protein cage with an 
external diameter of 12 nm and internal cavity of 8 nm.25,26 The heavy (H) subunits of AFt bind 
to the transferrin receptor 1 (TfR1),27,28 which is overexpressed in cancers (including gliomas) 
and is also abundantly present on the endothelium of the BBB.29,30 Hence, AFt has been 
proposed as an active drug delivery system for therapeutic agents across the BBB in vivo.31-33 
Indeed, there remains an urgent need to develop effective DDS formulations for TMZ and its 
analogs to enhance efficacy, overcome drug resistance and improve prognoses for patients 
diagnosed with brain malignancies.
Herein, we report the encapsulation of TMZ into AFt for GBM-targeted drug delivery, 
via TfR1 uptake. AFt has 14 channels (~ 0.3 – 0.4 nm in diameter) that enable encapsulation 
of small molecules by diffusion (the so-called ‘nanoreactor’ route). In vitro studies have been 
carried out on the isogenic GBM cancer cell line pair, MGMT-low (U373V) and MGMT-
transfected (U373M), together with MMR-deficient and Pgp overexpressing HCT116 
colorectal carcinoma (CRC) cell lines and non-tumorigenic MRC-5 lung fibroblasts. Enhanced 
activity of drug within cancerous cells over non-transformed cells upon treatment with 
encapsulated versus naked drug was demonstrated. Supported by detection of enhanced O6-
methylguanine (O6-MeG) adducts and H2AX foci in GBM cells exposed to AFt-encapsulated 
(compared to naked) TMZ, we attribute the observed differential cytotoxicity to AFt-related 
enhanced delivery, uptake and intracellular retention by cancer cells, allowing release of 
(intact) TMZ in acidic lysosomes. We additionally demonstrate that further enhancement of 
activity can be achieved by AFt encapsulation of the TMZ analog bearing the N3P substitution. 
Our results offer a novel approach for imidazotetrazine formulations that address current 
limitations, such as drug stability and tumor resistance, associated with TMZ chemotherapy. 
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62. MATERIALS AND METHODS
AFt-drug encapsulation: Initially, the reductive demineralization of horse spleen ferritin (Ft; 
92% L-subunit: 8% H-subunit) to AFt was carried out.34 TMZ (Sigma-Aldrich) and N3P 
(synthesized by Helen S. Summers, University of Nottingham) were encapsulated into AFt by 
diffusion. For both nano-formulations, drug solution in DMSO (10 mM, 7.2 μmoles of TMZ; 
6.3 μmoles of N3P) was added to AFt in 0.1 M sodium acetate (NaOAc) buffer (pH 5.5) 
solution (0.0045 mM, 0.009 μmoles) in small volume increments, every 30 mins (total time 4.5 
h), under stirring at 4 °C. The formulations were ultra-filtered using an Amicon ultra-4 
centrifugal filter (MWCO: 30 kDa) at 4000 x g for 4 mins and filtered through a 0.22 μm filter. 
Samples were stored at 4 °C for further studies.
Nanoparticle characterization: The hydrodynamic size and zeta potential of AFt and nano-
formulations diluted in deionized water were measured using Malvern Zetasizer Nano ZS 
(backscatter angle 173°, λ = 633 nm, T = 25 °C). Samples were filtered (0.22 μm filter) prior 
to reading and measured in a disposable DTS1070 cell. Protein size was corroborated via red 
native-PAGE, whereby proteins were stained prior to electrophoresis with Ponceau S (Sigma-
Aldrich) to impart negative charge whilst native structure was retained.35 Using a native PAGE 
4-16% Bis-Tris pre-cast gel (Invitrogen), samples (1 µg, 18 μL) alongside the NativeMark 
protein standard (Invitrogen, 5 μL) were resolved at 4 °C, for 1 h at 150 V followed by 1 h at 
250 V. Gels were stained with Coomassie brilliant blue G250 for 1 h and left to de-stain 
overnight in water before imaging with Gene flow limited.
Assessment of encapsulation efficiency and drug loading: Drug concentration in solution was 
estimated from absorbance measurements using Varian Cary 50 UV-Vis spectrophotometer (λ 
= 330 nm for TMZ and λ = 328 nm for N3P) with a Suprasil quartz cuvette (Hellma Analytics) 
and the protein concentration was determined by Bradford assay (see Supplementary Materials, 
SI1).36, 37 All measurements were performed in triplicate. For drug release studies, 400 µL of 
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7AFt nano-formulations were added into a Slide-A-Lyzer 10 kDa MWCO device (Thermo 
Fisher Scientific) and samples were dialyzed at 37 °C and mixed at 150 rpm against 14 mL of 
either pH 5.5 NaOAc buffer (0.1 M) or pH 7.4 phosphate buffered saline (PBS). After 1, 3, 5, 
7 and 24 h dialysis, drug concentration was measured by UV-Vis spectroscopy. Storage 
stability of AFt formulations at 4 °C, over 7 days, was also monitored for AFt and drug stability 
by using Malvern Zetasizer nano ZS, Bradford assay and UV-Vis spectrophotometer.
Cell culture studies: Human cell lines used include GBM, U373V (MGMT -) and U373M 
(MGMT +) (gifted by Schering Plough Corporation), colorectal carcinoma (CRC) HCT116 
(MGMT +; hMLH1 -) and HCT116 VR (vincristine resistant; Pgp +)38 and non-tumorigenic 
fetal lung fibroblast, MRC-5 (American Type Tissue Collection (ATCC)) cell lines. GBM cells 
were cultured in RPMI-1640 medium with 10% v/v fetal bovine serum (FBS), 1% v/v non-
essential amino acids (NEAA), 50 μg/mL gentamicin and 400 μg/mL G418 (Corning). 
HCT116 cells were cultured in RPMI-1640 medium with 10% v/v FBS and MRC-5 cells were 
cultured in minimum essential medium (MEM) with 10% v/v FBS, 1% v/v NEAA, 1% v/v 
penicillin/streptomycin, 2 mM L-glutamine, 10 mM Hepes buffer and 0.075% v/v sodium 
bicarbonate. Cells were maintained in 5% CO2 at 37 °C. All media and cell culture assay 
components except where otherwise specified were purchased from Sigma-Aldrich.
Growth inhibition of cells was monitored using the 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) assay. The MTT assay was performed in 96-well plates 
following 6-day test agent (naked drug, encapsulated drug and naked vehicle) exposure, and at 
the time of treatment at time zero (T0). Seeding densities for GBM cells were 650 cells/well 
and for HCT116 and MRC-5 cells, 400 cells/well. Test agent was introduced into wells (5 
replicates per concentration) 24 h after cell-seeding. MTT reagent (400 μg/ml, Alfa Aesar) was 
added to each well and plates were incubated for 2 h at 37 °C.  After 2 h, medium containing 
non-metabolized MTT was aspirated and the insoluble formazan product was dissolved in 
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8DMSO (150 μL). Plates were placed on an orbital shaker for 5 mins and the absorbance was 
measured at λ = 570 nm with the Perkin Elmer Envision plate reader. At least 3 independent 
repeats for each test agent were performed. 
For clonogenic assays, cells were seeded in 6-well plates (400 cells/well) and were exposed to 
TMZ, AFt-TMZ and AFt (50 μM TMZ; 0.057 μM AFt) for 24 h and 6 days. Thereafter, 
medium containing test agent was removed, cells were washed with PBS and fresh medium 
was introduced into wells. Plates were incubated at 37 °C and the assays terminated when 
colonies of ≥ 50 cells were observed in control wells. Colonies were washed with PBS, fixed 
with 100% methanol, stained with 0.05% methylene blue and counted. Duplicate repeats for 
each test agent were performed in at least 3 independent trials. 
For live cell counts, GBM cells were seeded in 6-well plates at 1 x 104 cells/well and treated 
with TMZ, AFt-TMZ (TMZ: 50 μM; AFt: 0.057 μM) and AFt vehicle (0.057 μM) for 6 days. 
Then cells were collected by centrifugation (1200 rpm, 5 mins, 4 °C). Live cells were counted 
with a hemocytometer using trypan blue (Sigma-Aldrich). 
Flow cytometry was carried out to examine cell cycle and for γH2AX foci analysis on GBM 
cells. For cell cycle analysis, cells were seeded in 6-well plates at 1 x 105 cells/well and  treated 
with TMZ, AFt-TMZ (TMZ: 50 μM; AFt: 0.057 μM) and AFt (0.057 μM) for 72 h. Cells were 
collected and washed with PBS by centrifugation (1200 rpm, 5 mins, 4 °C). Cells were then 
incubated overnight at 4 °C, in the dark, with 500 μL of hypertonic fluorochrome solution 
(0.1% sodium citrate, 0.1% triton X-100, 50 μg/mL propidium iodide (PI) and 0.1 mg/mL 
ribonuclease A (RNase A) in deionized water). For γH2AX foci analysis, cells were seeded in 
10 cm tissue culture treated Petri dish at 5 x 105 cells/dish and treated with TMZ, AFt-TMZ 
(TMZ: 50 μM; AFt: 0.057 μM and 100 μM; AFt: 0.1 μM) and AFt (0.057 and 0.1 μM) for 48 
and 72 h. Cells were collected and stained using mouse anti-human phospho-histone H2A.X 
(Ser139) primary antibody (1o Ab), clone JBW301 (1:3333; Merck) and F(ab')2-goat anti-
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9mouse IgG, IgM (H+L) Alexa-Fluor 488 secondary (2o) Ab (1:1750; Invitrogen). The 
fluorescence of 10000 mean gated events (single cells) was obtained using the Beckman 
Coulter FC500 flow cytometer. The data were processed using Weasel v3.0.2 software. 
Indirect enzyme-linked immunosorbent assay (ELISA) was carried out for DNA O6-MeG 
quantification in GBM cells. Cells were seeded in 6-well plates at 0.1-1 x 105 cells/well and 
treated with TMZ and AFt-TMZ (50 μM) for 4, 24, 72 and 144 h. The purification of DNA 
from cells was carried out using the QIAGEN Blood & Cell Culture DNA mini purification 
kits, following the manufacturer’s procedure. Double-stranded DNA (1 µg) was then digested 
with the Timesaver MspI restriction enzyme kit (New England Biolabs), following the 
manufacturer’s procedure, and made single-stranded by heating at 95 °C for 10 mins before 
rapidly transferring to ice for at least 15 mins. ELISA was then performed using the IgG (Total) 
Mouse Uncoated ELISA kit (Invitrogen), following the manufacturer’s procedure with some 
modifications. Briefly, a 96-well plate was pre-coated with 1% w/v protamine sulfate (Sigma-
Aldrich) at RT for 1 h, removed and washed 5 times with a jet of milli-Q water. Wells were 
then coated with DNA (10 ug/mL; 100 µL) diluted in coating buffer 1x and incubated overnight 
on a shaker at RT. Wells were washed (3x) with eBioscience wash buffer 1x (Invitrogen) and 
blocked with blocking buffer 2x for 2 h, at room temperature (RT). Samples were incubated 
with the 1o monoclonal Ab, mouse anti-human O6-MeG (0.2 µg/mL; Axxora) for 1.5 h at RT, 
followed by incubation with 2o HRP-conjugated anti-mouse IgG polyclonal Ab (1:250) for 1 h 
at RT. Wells were then treated with the tetramethylbenzidine (TMB) substrate solution (100 
µL) for 15 mins at RT in the dark, quenched with stop solution (100 µL; Invitrogen) for 5 mins 
at RT and absorbance read at λ = 450 nm on a Perkin Elmer Envision plate reader. At least 3 
independent repeats for each test agent were performed. 
Western blot: For protein extraction, cells were collected by centrifugation (1200 rpm, 5 mins, 
4 °C) and lysed in Nonidet-P40 lysis buffer. Protein concentrations were determined by 
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10
Bradford assay.36,37 Protein fractions (50 μg) were separated by SDS-PAGE (10% resolving 
gel), transferred onto a nitrocellulose membrane (GE Healthcare Life Sciences) using the 
Trans-Blot Turbo Transfer System (Bio-Rad) and blocked in 5% skimmed milk in TBST (tris-
buffered saline, Tween 20) for 1 h. Membranes were incubated at 4 °C overnight with the 
following monoclonal 1o Abs, rabbit anti-human TfR1 (1:1000), MGMT (1:1000), 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH; loading control; 1:1000) (all from Cell 
Signaling Technology), mouse anti-human Scavenger Receptor Class A Member 5 (SCARA5; 
1:1000) and transferrin receptor 2 (TfR2; 1:250) (both from R&D systems a bio-techne brand). 
Membranes were then incubated with 2o Ab (1:4000) for 1 h at RT using either goat anti-rabbit 
or goat anti-mouse polyclonal antibodies conjugated with horseradish peroxidase (Dako). 
Bands were visualized on a C-DiGit blot scanner (LI-COR Biosciences) after incubating the 
membranes with ECL reagent (GE Healthcare) for 5 mins.
Imaging cellular morphology: For environmental scanning electron microscopy (ESEM), a 
TGS1x0.2 Gold Slot grid (EM Resolutions) was placed at the bottom of a 6-well plate and cells 
were seeded at 1 x 105 cells/well. After 24 h exposure to TMZ and AFt-TMZ (50 μM), cells 
were fixed with 3.7% v/v formaldehyde in PBS for 5 mins. The grids were washed and stored 
in PBS. Immediately prior to imaging, grids were rinsed with deionized water and mounted on 
a stage set at 3 °C. The chamber pressure was dropped to 5.15 Torr, with humidity set to 87 %. 
Images were acquired using FEI Quanta 650 ESEM operating using a 5 kV electron beam and 
magnification x1000. For confocal microscopy, GBM cells were seeded in an 8-well μ-slide 
plate (Ibidi) at 1 x 104 cells/well and treated for 24 h with TMZ and AFt-TMZ (50 μM). 
Following treatment, cells were washed with PBS, fixed with 3.7% v/v formaldehyde (15 mins) 
and permeabilized with 0.1% v/v triton X-100. Cells were then co-stained for 1 h with F-actin 
phalloidin-iFluor 633 (1x) and nuclear DAPI (0.02 μg/ml) stains. Wells were washed twice 
with PBS before storing in PBS (200 μL) for imaging. Imaging was performed with a 63x water 
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11
magnification lens using Zeiss Elyra PS1 super resolution microscope with DAPI excitation at 
405 nm and phalloidin excitation at 633 nm. Confocal images were analyzed using the Fiji 
Image J software.
Statistical analysis. Two-way or three-way ANOVA analysis function on GraphPad Prism 
version 8.2.1 was used to determine the differences between multiple groups (n ≥ 3). Values of 
*P or #P < 0.05, **P or ##P < 0.01, ***P or ###P < 0.001 and ****P or ####P < 0.0001 were 
considered as statistically significant. Data are represented as the means ± SD. 
3. RESULTS AND DISCUSSION
The AFt protein cage has an external diameter ~ 12 nm suitable for passive targeting via the 
enhanced permeability and retention (EPR) effect.39 TfR1 binding sites on the H-polypeptide 
subunits of AFt allow active targeting of AFt-encapsulated cargo. TfR1 has been shown to be 
overexpressed by GBM (but not glial) and present on BBB endothelial cells, but not peripheral 
endothelium.30 TfR1 has been shown to be an important receptor for cancers due to their 
increased iron demand.40 We hence evaluated the loading of TMZ into AFt for GBM targeting, 
with the goal to achieve enhanced transport of the molecules across the BBB, delivery to, and 
accumulation within cancer cells. AFt-encapsulation of TMZ may also minimize premature 
degradation and elimination, efflux (mediated by Pgp) and drug-related side effects. The small 
size of the test agent (< 300 g/mol) allows its encapsulation via the ‘nanoreactor’ route, where 
passive diffusion across the 0.3 - 0.4 nm channels is feasible.37,41,42 Briefly, test agent was 
added gradually over 4.5 h to AFt at pH 5.5 to permit encapsulation under diffusion to take 
place (Figure 1b) and to avoid TMZ degradation, which occurs at physiological pH ~ 7.4 (in 
vitro t½ of TMZ at pH 7.4 is 1.9 h;8 at pH 5.5 t½ > 100 h). We achieved 84.3 ± 5.2% 
encapsulation efficiency (EE) and 18.7 ± 2.3% drug loading (DL), which corresponds to ~ 520 
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drug molecules per AFt cage (see also Supplementary Information, SI1). The integrity of the 
AFt cage following drug encapsulation and absence of drug attachment to the AFt exterior was 
confirmed by DLS and zeta potential measurements; no noticeable change in either 
hydrodynamic size or zeta potential was observed, with average hydrodynamic diameter of 
13.3 ± 0.9 nm and zeta potential of -12.7 ± 0.3 mV for AFt before and after TMZ encapsulation 
(Figure 1c). Native PAGE of AFt-TMZ revealed protein bands at molecular weight (MW) ~ 
480 and 720 kDa (dimer), comparable to those of AFt alone (Figure 1d), confirming successful 
encapsulation of the agents inside the AFt cavity. By optimizing the encapsulation conditions 
and performing step-wise addition of the drug, we achieved improved drug loading (~ 520 
molecules per AFt cage) compared to previously reported values of up to 100 – 350 molecules 
of GW608 and its derivatives and 185 molecules of triazene, 5-(3-methyltriazen-1-yl) 
imidazole-4-carboxamide (MTIC).37,43 We attribute enhanced DL, to the small molecular 
weight and good solubility profiles of TMZ.
We assessed the release of drugs from AFt under physiologically relevant conditions 
(T = 37 °C, pH 7.4 and pH 5.5; see Supplementary Information SI1, Figure S2) and observed 
slower drug release within the first 3 h at pH 7.4 compared to pH 5.5. This observation is 
consistent with the expectation that AFt channels are narrower at more alkali pH and gradually 
widen as the capsule relaxes with increasing acidity.44 The storage stability of the AFt 
formulation (at T = 4 °C) was monitored and no apparent change in protein size, zeta potential 
or drug:AFt ratio were observed over a period of at least 7 days (Supplementary Information 
SI1, Figure S3). 
The in vitro anti-cancer activity of TMZ delivered by AFt was subsequently evaluated. 
Initially, MTT assays were employed and the following cell lines utilized for our studies: 
U373V (MGMT -), U373M (MGMT +) GBM; HCT116 (MMR deficient), HCT116 VR (Pgp 
+) CRC and non-cancerous MRC-5 fibroblasts. The growth inhibitory activity of AFt-TMZ 
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was compared to unencapsulated (naked) TMZ. The cells were exposed to test agent with 
concentrations ranging from 0.001 - 1000 µM. Cellular growth inhibition (estimated GI50 
values) was determined (Figure 2). Cells were exposed to test agents for 6 days, allowing 
enough time for a minimum of 2 cell cycle rounds, DNA methylation and MMR activation. 
AFt-TMZ demonstrated markedly enhanced activity over naked TMZ. GI50 values of 35 µM 
and 376 µM were calculated for TMZ in U373V and U373M cells respectively. Remarkably, 
AFt-TMZ demonstrated significantly lower GI50 values (enhanced activity) of < 1.5 µM in both 
U373V and U373M cell lines. Of interest, and contrary to expectations, AFt-encapsulated TMZ 
displayed enhanced activity over naked TMZ in cell lines that showed resistance to TMZ, 
where resistance was conferred by MGMT (532-fold enhanced activity in U373M), MMR loss 
(22-fold in HCT116) and additionally Pgp expression (24-fold in HCT116 VR). 
Cancer-selective activity was also seen, with AFt-TMZ demonstrating enhanced 
activity against cancer cells over fibroblasts by ~ 5-fold. Alone, AFt did not display growth 
inhibitory activity against any of the cell lines at concentrations ≤ 1 µM (equivalent to the 
highest concentration of AFt in AFt-drug used in the assay). In support of this study, live cell 
count assays (Supplementary Information, SI2) demonstrated greater significant loss of viable 
cells with AFt-TMZ treatment against U373M compared to naked TMZ (P < 0.0001). 
Interestingly, Fang et al. demonstrated that conjugation of TMZ to chitosan nanoparticles could 
partially overcome TMZ-resistance.23 Kumari et al. also reported this phenomenon with TMZ-
loaded lactoferrin nanoparticles.24 Recently reported is the AFt-encapsulation of the combined 
TMZ-intermediate, MTIC, with copper.43 We postulate that the enhanced activity of TMZ 
encapsulated within AFt is due to a different mode of cellular uptake (via TfR1 recognition). 
AFt rapidly enters and accumulates inside lysosomes following TfR1 receptor mediated 
endocytosis,27 therefore evasion of Pgp efflux may be possible. Consequently, enhanced 
intracellular accumulation of TMZ results in greater potency. 
Page 13 of 32
ACS Paragon Plus Environment
ACS Applied Materials & Interfaces
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
14
In order to test this hypothesis, we examined cellular expression of proteins responsible 
for AFt uptake and resistance to TMZ. Protein lysates prepared from the cancer cells used in 
this study revealed TfR1 expression whereas in MRC-5 lysates, expression was below the limit 
of detection (Figure 3 and supplementary Figure S5). Since the expression of SCARA5 and 
TfR2 was not observed, we conclude that TfR1 is the receptor responsible for AFt uptake, 
providing some selective anti-cancer activity for our formulation. Western blot also confirmed 
the presence of MGMT, which confers TMZ resistance, in U373M and its absence in U373V.
To substantiate the results of AFt-TMZ activity against TMZ-resistant U373M, 
clonogenic assays were employed. Figure 4 illustrates the survival fraction of U373V and 
U373M colonies after 24 h and 6 days exposure to naked and encapsulated TMZ (see also 
Supplementary Information SI2). AFt alone had negligible effect on colony numbers 
confirming the biocompatibility of this drug delivery vehicle, however, AFt-encapsulation of 
TMZ augmented the drug`s inhibition of colony formation in both U373V and U373M GBM 
cells. TMZ alone (50 µM) potently inhibited U373V colony formation by 68% and 84% after 
24 h and 6 d exposure, respectively; whereas, U373M cells demonstrated much greater 
resistance to naked TMZ challenge (colony formation inhibited by 14% and by 35% after 24 h 
and 6 d exposure, respectively). In contrast, 24 h and 6 d AFt-TMZ exposure potently inhibited 
U373M colony formation by 47% and 76% respectively. U373M cells were significantly less 
able to survive AFt-TMZ challenge (compared to naked TMZ) and form progeny colonies; 
AFt-TMZ displayed 2.7-fold enhanced toxicity compared to naked TMZ, supporting MTT 
assays and cell counts further demonstrating that AFt-delivery of TMZ is able to weaken tumor 
resistance to TMZ mediated by MGMT.   
Following the assessment of AFt-TMZ cytotoxicity, GBM cell cycle progression was 
probed after 72 h exposure of cells to TMZ and AFt-TMZ. Treatment periods of 72 h were 
adopted to allow cells to complete at least one division for detection of putative cell cycle 
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perturbation by AFt-TMZ. It is known that TMZ (in the absence of MGMT) alkylates DNA 
causing S and G2/M arrest.13,14 G2/M arrest can be seen following treatment with TMZ in 
U373V cells only; however, both U373V and U373M cells expressed greater G2/M- and S-
phase arrest following exposure to AFt-TMZ (Figure 5a, and Supplementary Information, 
SI2). Compared to U373V control populations, S-phase arrest was increased by ~ 2.5- and 2.6-
fold with TMZ and AFt-TMZ, respectively; G2/M-phase arrest was increased by ~ 2.3- and 
2.8-fold, respectively. As for U373M, S- and G2/M-phase arrest was increased by 1.87- and 2-
fold, respectively, following treatment with AFt-TMZ. TMZ alone failed to significantly 
perturb U373M cell cycle progression. Cell cycle profiles indistinguishable from controls were 
observed following exposure of cells to AFt alone. Assessment of O6-MeG levels in the DNA 
of cells following treatment with TMZ and AFt-TMZ (4 – 144 h), revealed that AFt-TMZ 
delivered significantly more (P < 0.001) methyl groups to O6-guanine then TMZ alone (Figure 
5b). 
Since AFt-TMZ was shown to transcend the resistance systems in GBM cells, evoking 
significantly enhanced activity over TMZ alone, we sought to establish whether the increased 
O6-MeG levels and S- and G2/M-phase arrest translated to greater DNA damage following 
treatment for 48 and 72 h. The presence of γH2AX foci is indicative of DNA double strand 
breaks and as such, our studies have demonstrated that greater levels of γH2AX foci were 
observed following treatment of U373V and U373M cells with AFt-TMZ (compared to TMZ 
alone; Figure 5c). These levels were shown to increase in both a time- and concentration-
dependent manner. In U373V and U373M, 72 h exposure to 50 µM AFt-TMZ yielded 
respectively 1.2- and 1.4-fold significantly more DNA double strand breaks over TMZ alone 
(P < 0.001). This corroborated well with the trends observed in cell cycle and O6-MeG 
analyses.
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We further evaluated the effect of AFt-TMZ treatment on GBM cells using ESEM in 
order to observe changes to the cell surface after brief exposure of cells to test agents. It was 
apparent that the spread of the cells was greatly affected by AFt-TMZ, more so than by naked 
TMZ after 24 h treatment exposure (Figure 6). In contrast to the control cells, those treated 
with AFt-TMZ appeared more shrunken, with blebs apparent on their surfaces; being most 
obvious on U373M. Confocal microscopy studies carried out on stained actin filaments using 
phalloidin further corroborated the ESEM work. The intensity of the phalloidin stain was at its 
lowest with AFt-TMZ; a more shrunken cellular morphology most likely indicates reduced 
uptake of F-actin stain (Supplementary Information, SI2, Figure S9). Cell shrinkage and 
blebbing may signify apoptosis. F-actin cytoskeleton is an essential component in regulation 
of cell shape, migration and division and its reduction infers loss of these capabilities.45 These 
methodologies have demonstrated that AFt-TMZ affects cellular morphology as early as 24 h 
post treatment.
The promising, enhanced anti-cancer activity achieved with AFt-TMZ encouraged us 
to pursue AFt-encapsulation of N3P, an analog of TMZ where N3-methyl has been replaced 
with a propargyl moiety (Figure 7). N3P was designed to deliver propargyl lesions onto 
susceptible DNA bases that cannot be removed by MGMT. Indeed, TAQ polymerase assays 
demonstrated alkylation at runs of guanine – akin to those caused by TMZ, and anti-tumor 
activity was seen irrespective of MGMT or MMR status.19,20 However, N3P possesses inferior 
(in comparison to TMZ) pharmacokinetic properties (t½ = 49 min at pH 7.4), potentially 
thwarting efficient delivery to the brain and therapeutic utility. Like TMZ, N3P is acid-stable 
(t½ > 100 h at pH 5.5), therefore, N3P was encapsulated within AFt cages using the same 
diffusion method optimized for TMZ. Similar loading efficiency of ~ 525 molecules per AFt 
capsule was achieved (EE = 70.5 ± 3.3% and DL = 20.5 ± 3.1%). No noticeable change in 
hydrodynamic size and zeta potential was observed, with average hydrodynamic diameter of 
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13.1 ± 0.7 nm and zeta potential of -12.5 ± 0.4 mV for AFt before and after N3P encapsulation 
(Figure 7a). Native PAGE of AFt-N3P revealed protein bands at MW ~ 480 and 720 kDa, 
comparable to those of AFt alone; confirming successful encapsulation of the agent inside the 
AFt cavity. In vitro growth inhibitory studies on GBM cell lines, U373V (MGMT –) and 
U373M (MGMT +), HCT 116 (MMR deficient) and non-cancerous MRC-5 fibroblasts (Figure 
7b) demonstrated enhanced activity with lower GI50 values compared to TMZ in both GBM 
cell lines: GI50 value of < 0.25 µM for AFt-N3P. The AFt-N3P formulation retained a degree 
of selectivity, with ~ 9-fold greater activity in cancer cells compared to fibroblasts. 
Therefore, development of AFt-formulations of TMZ and N3P represents a promising 
strategy to challenge TMZ resistance in malignant brain tumors such as GBM, and wider 
spectrum cancer phenotypes. Furthermore, the surface of AFt can be modified with additional 
surface ligands (e.g. GKRK peptides) for enhanced tumor accumulation in vivo and BBB 
penetrance.31,46 Preclinical effects of AFt delivery of imidazotetrazine molecules will be further 
evaluated in vivo.
4. CONCLUSIONS
In conclusion, we have successfully loaded > 500 molecules of TMZ and N3P per AFt cage, 
via the nanoreactor route, achieving EE > 70% and DL > 18%, and maintaining AFt capsule 
integrity. In vitro studies demonstrated that both AFt nano-formulations displayed significantly 
enhanced activity over naked drugs against MGMT +/- GBM cell lines. Most intriguingly, this 
includes AFt-TMZ, which in vitro overcame tumor resistance mediated by MGMT. 
Accumulation of O6-MeG adducts, cell cycle arrest and subsequent generation of γH2AX in 
U373M support the hypothesis that TfR1, expressed by cancer cell lines used in this study, 
mediates increased intracellular accumulation of TMZ that is able to overwhelm the suicide 
repair protein MGMT and confer sensitivity to TMZ in MGMT + GBM cells. If O6-guanine 
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methylation outpaces MGMT protein synthesis, its depletion would ensue 47 – as is indicated 
following exposure of U373M cells to AFt-TMZ (Bouzinab unpublished results). Moreover, 
evidence suggests other mechanisms conferring tolerance or resistance to TMZ may be 
weakened (including MMR-deficiency and Pgp expression) following its encapsulation in AFt. 
In addition, AFt encapsulation of imidazotetrazine analog N3P resulted in enhanced anti-tumor 
activity and cancer cell line-selectivity. Importantly, AFt alone was non-toxic. These findings 
lay the foundations for AFt, a biocompatible, species-specific nanosized biomaterial with built 
in targeting, to deliver concentrated amounts of anti-cancer small molecules to tumors. 
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Figure 1. (a) Chemical structures of TMZ and N3P. (b) Illustration of the encapsulation of 
TMZ into AFt by the nanoreactor route. (c) Hydrodynamic size distribution of AFt and AFt-
TMZ measured by dynamic light scattering and (Inset) corresponding zeta potential values. (d) 
Native-PAGE of AFt and AFt-TMZ performed on a 4-16% gradient gel.  
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a) b)
Figure 2. (a) In vitro cytotoxicity profiles for U373M (GBM cells, MGMT +) and non-
cancerous MRC 5 fibroblasts following 6-day exposure to AFt, TMZ and AFt-TMZ. (b) A 
summary of GI50 values for TMZ and AFt-TMZ in all studies cell lines. Values are reported as 
mean ± SD (n > 3). **P < 0.01 and ****P < 0.0001.
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Figure 3. Cellular characterization of protein expression. (a) Western blot analysis of 
membrane bound receptors responsible for AFt uptake and intracellular proteins responsible 
for TMZ resistance. (b) Quantification of target protein band intensity expressed as a ratio of 
target protein to loading control (GAPDH) band intensity using the LICOR software. Values 
are reported as mean ± SD (n = 3). Significant difference from MRC-5 are expressed as ****P 
< 0.0001; Significant difference from U373V is expressed as ####P < 0.0001.  
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Figure 4. In vitro characterization of cell proliferation proficiency following treatment. (a) 
Representative images of the clonogenic assay conducted on U373M for a 6-day treatment 
(TMZ 50 µM, AFt-TMZ 50 µM, AFt 0.057 µM or media alone) exposure. (b) Percentage 
survival fraction of GBM; MGMT +/- cells following either a 24 h or 6-day treatment regimen 
with 1, 10 or 50 µM TMZ/ AFt-TMZ and 0.057 µM AFt (equivalent to AFt concentration of 
AFt-TMZ 50 µM). Values are reported as mean ± SD (n = 5). Significant difference from the 
control are expressed as *P < 0.05, **P < 0.01, ***P < 0.001 and ****P < 0.0001. Significant 
difference from TMZ are expressed as # P < 0.05.  ####P < 0.0001. 
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Figure 5. The mechanism of action of TMZ versus AFt delivered TMZ in GBM, MGMT +/- 
cells. (a) Summary of the number of gated events i.e. cells (expressed as a percentage from 
10000 gated events), arrested in different phases of the cell cycle after 72 h treatment (TMZ 50 
µM, AFt-TMZ 50 µM, AFt 0.057 µM or media alone) exposure. (b) ELISA DNA O6-MeG 
quantification following exposure of cells to 50 µM of TMZ or AFt-TMZ. (c) Summary of the 
fluorescence intensity of γH2AX foci (expressed as a percentage from 10000 gated events), 
after a 48 or 72 h treatment exposure to 50 or 100 µM of TMZ and AFt-TMZ and 0.057 or 0.1 
µM of AFt. Values are reported as mean ± SD (n = 3). Significant difference from the control 
are expressed as *P < 0.05, ***P < 0.001 and ****P < 0.0001. Significant difference from 
TMZ are expressed as ###P < 0.001. 
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Figure 6. Morphological changes to GBM cells following 24 h treatment exposure (TMZ/ AFt-
TMZ 50 µM). Cell surface morphology was monitored by a combination of ESEM and 
confocal microscopy (phalloidin (red) - F-actin staining; DAPI (blue) – nucleus staining). Scale 
bar is 50 µm. 
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Figure 7. (a) Hydrodynamic size distribution of AFt and AFt-N3P measured by dynamic light 
scattering and (inset) corresponding zeta potential measurements. In addition, native-PAGE 
carried out on AFt and AFt-N3P showing protein integrity was performed on a 4-16% gradient 
gel. (b) In vitro cytotoxicity MTT studies with naked and encapsulated N3P (TMZ analog; 
inset chemical structure shown). Summary of concentration values leading to growth inhibition 
at 50% (GI50) for test agents against GBM (MGMT +/-), HCT116 (MMR -) and non-cancerous 
MRC-5 cells. Values are reported as mean ± SD (n=5). ****P < 0.0001.
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